3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Classical hematology
2
Conditions
Lymphoproliferative Disorders
2
Anemia, Iron-Deficiency
2
Anemia
2
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
ferric carboxymaltose
×
Lymphoid
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled